Growth hormone receptor polymorphism and growth hormone therapy response in children: A bayesian meta-analysisCitation formats

  • External authors:
  • Mattea Solomon
  • Marcel Zwahlen
  • Reena Morjaria
  • Laura Audí
  • Gerhard Binder
  • Werner Blum
  • Pierre Bougnres
  • Christine Dos Santos
  • Antonio Carrascosa
  • Anita Hokken-Koelega
  • Alexander Jorge
  • Primus E. Mullis
  • Maïthé Tauber
  • Leena Patel

Standard

Growth hormone receptor polymorphism and growth hormone therapy response in children: A bayesian meta-analysis. / Renehan, Andrew G.; Solomon, Mattea; Zwahlen, Marcel; Morjaria, Reena; Whatmore, Andrew; Audí, Laura; Binder, Gerhard; Blum, Werner; Bougnres, Pierre; Santos, Christine Dos; Carrascosa, Antonio; Hokken-Koelega, Anita; Jorge, Alexander; Mullis, Primus E.; Tauber, Maïthé; Patel, Leena; Clayton, Peter E.

In: American Journal of Epidemiology, Vol. 175, No. 9, 01.05.2012, p. 867-877.

Research output: Contribution to journalArticle

Harvard

Renehan, AG, Solomon, M, Zwahlen, M, Morjaria, R, Whatmore, A, Audí, L, Binder, G, Blum, W, Bougnres, P, Santos, CD, Carrascosa, A, Hokken-Koelega, A, Jorge, A, Mullis, PE, Tauber, M, Patel, L & Clayton, PE 2012, 'Growth hormone receptor polymorphism and growth hormone therapy response in children: A bayesian meta-analysis', American Journal of Epidemiology, vol. 175, no. 9, pp. 867-877. https://doi.org/10.1093/aje/kwr408

APA

Vancouver

Renehan AG, Solomon M, Zwahlen M, Morjaria R, Whatmore A, Audí L et al. Growth hormone receptor polymorphism and growth hormone therapy response in children: A bayesian meta-analysis. American Journal of Epidemiology. 2012 May 1;175(9):867-877. https://doi.org/10.1093/aje/kwr408

Author

Renehan, Andrew G. ; Solomon, Mattea ; Zwahlen, Marcel ; Morjaria, Reena ; Whatmore, Andrew ; Audí, Laura ; Binder, Gerhard ; Blum, Werner ; Bougnres, Pierre ; Santos, Christine Dos ; Carrascosa, Antonio ; Hokken-Koelega, Anita ; Jorge, Alexander ; Mullis, Primus E. ; Tauber, Maïthé ; Patel, Leena ; Clayton, Peter E. / Growth hormone receptor polymorphism and growth hormone therapy response in children: A bayesian meta-analysis. In: American Journal of Epidemiology. 2012 ; Vol. 175, No. 9. pp. 867-877.

Bibtex

@article{7c65615c525b4be6a6f3661aa3f98a9a,
title = "Growth hormone receptor polymorphism and growth hormone therapy response in children: A bayesian meta-analysis",
abstract = "Recombinant human growth hormone (rhGH) therapy is used in the long-term treatment of children with growth disorders, but there is considerable treatment response variability. The exon 3-deleted growth hormone receptor polymorphism (GHR d3) may account for some of this variability. The authors performed a systematic review (to April 2011), including investigator-only data, to quantify the effects of the GHR fl-d3 and GHR d3-d3 genotypes on rhGH therapy response and used a recently established Bayesian inheritance model-free approach to meta-analyze the data. The primary outcome was the 1-year change-in-height standard-deviation score for the 2 genotypes. Eighteen data sets from 12 studies (1,527 children) were included. After several prior assumptions were tested, the most appropriate inheritance model was codominant (posterior probability = 0.93). Compared with noncarriers, carriers had median differences in 1-year change-in-height standard-deviation score of 0.09 (95{\%} credible interval (CrI): 0.01, 0.17) for GHR fl-d3 and of 0.14 (95{\%} CrI: 0.02, 0.26) for GHR d3-d3. However, the between-study standard deviation of 0.18 (95{\%} CrI: 0.10, 0.33) was considerable. The authors tested by meta-regression for potential modifiers and found no substantial influence. They conclude that 1) the GHR d3 polymorphism inheritance is codominant, contrasting with previous reports; 2) GHR d3 genotypes account for modest increases in rhGH effects in children; and 3) considerable unexplained variability in responsiveness remains. {\circledC} 2012 The Auther.",
keywords = "Bayesian meta-analysis, genetic model, growth hormone, growth hormone receptor polymorphism",
author = "Renehan, {Andrew G.} and Mattea Solomon and Marcel Zwahlen and Reena Morjaria and Andrew Whatmore and Laura Aud{\'i} and Gerhard Binder and Werner Blum and Pierre Bougnres and Santos, {Christine Dos} and Antonio Carrascosa and Anita Hokken-Koelega and Alexander Jorge and Mullis, {Primus E.} and Ma{\"i}th{\'e} Tauber and Leena Patel and Clayton, {Peter E.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1093/aje/kwr408",
language = "English",
volume = "175",
pages = "867--877",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Growth hormone receptor polymorphism and growth hormone therapy response in children: A bayesian meta-analysis

AU - Renehan, Andrew G.

AU - Solomon, Mattea

AU - Zwahlen, Marcel

AU - Morjaria, Reena

AU - Whatmore, Andrew

AU - Audí, Laura

AU - Binder, Gerhard

AU - Blum, Werner

AU - Bougnres, Pierre

AU - Santos, Christine Dos

AU - Carrascosa, Antonio

AU - Hokken-Koelega, Anita

AU - Jorge, Alexander

AU - Mullis, Primus E.

AU - Tauber, Maïthé

AU - Patel, Leena

AU - Clayton, Peter E.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Recombinant human growth hormone (rhGH) therapy is used in the long-term treatment of children with growth disorders, but there is considerable treatment response variability. The exon 3-deleted growth hormone receptor polymorphism (GHR d3) may account for some of this variability. The authors performed a systematic review (to April 2011), including investigator-only data, to quantify the effects of the GHR fl-d3 and GHR d3-d3 genotypes on rhGH therapy response and used a recently established Bayesian inheritance model-free approach to meta-analyze the data. The primary outcome was the 1-year change-in-height standard-deviation score for the 2 genotypes. Eighteen data sets from 12 studies (1,527 children) were included. After several prior assumptions were tested, the most appropriate inheritance model was codominant (posterior probability = 0.93). Compared with noncarriers, carriers had median differences in 1-year change-in-height standard-deviation score of 0.09 (95% credible interval (CrI): 0.01, 0.17) for GHR fl-d3 and of 0.14 (95% CrI: 0.02, 0.26) for GHR d3-d3. However, the between-study standard deviation of 0.18 (95% CrI: 0.10, 0.33) was considerable. The authors tested by meta-regression for potential modifiers and found no substantial influence. They conclude that 1) the GHR d3 polymorphism inheritance is codominant, contrasting with previous reports; 2) GHR d3 genotypes account for modest increases in rhGH effects in children; and 3) considerable unexplained variability in responsiveness remains. © 2012 The Auther.

AB - Recombinant human growth hormone (rhGH) therapy is used in the long-term treatment of children with growth disorders, but there is considerable treatment response variability. The exon 3-deleted growth hormone receptor polymorphism (GHR d3) may account for some of this variability. The authors performed a systematic review (to April 2011), including investigator-only data, to quantify the effects of the GHR fl-d3 and GHR d3-d3 genotypes on rhGH therapy response and used a recently established Bayesian inheritance model-free approach to meta-analyze the data. The primary outcome was the 1-year change-in-height standard-deviation score for the 2 genotypes. Eighteen data sets from 12 studies (1,527 children) were included. After several prior assumptions were tested, the most appropriate inheritance model was codominant (posterior probability = 0.93). Compared with noncarriers, carriers had median differences in 1-year change-in-height standard-deviation score of 0.09 (95% credible interval (CrI): 0.01, 0.17) for GHR fl-d3 and of 0.14 (95% CrI: 0.02, 0.26) for GHR d3-d3. However, the between-study standard deviation of 0.18 (95% CrI: 0.10, 0.33) was considerable. The authors tested by meta-regression for potential modifiers and found no substantial influence. They conclude that 1) the GHR d3 polymorphism inheritance is codominant, contrasting with previous reports; 2) GHR d3 genotypes account for modest increases in rhGH effects in children; and 3) considerable unexplained variability in responsiveness remains. © 2012 The Auther.

KW - Bayesian meta-analysis

KW - genetic model

KW - growth hormone

KW - growth hormone receptor polymorphism

U2 - 10.1093/aje/kwr408

DO - 10.1093/aje/kwr408

M3 - Article

VL - 175

SP - 867

EP - 877

JO - American Journal of Epidemiology

T2 - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 9

ER -